Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 97Myelodysplastic Syndromes 73Precursor Cell Lymphoblastic Leukemia-Lymphoma 61Leukemia, Lymphocytic, Chronic, B-Cell 59Leukemia 55Lymphoma, Non-Hodgkin 45Lymphoma 43Leukemia, Myelogenous, Chronic, BCR-ABL Positive 43Multiple Myeloma 42Hodgkin Disease 38Hematologic Neoplasms 35Myeloproliferative Disorders 24Melanoma 22Lymphoma, Mantle-Cell 18Recurrence 17Lymphoma, Follicular 17Neoplasms 16Lymphoma, Large B-Cell, Diffuse 15Primary Myelofibrosis 14Lymphoma, B-Cell 14Burkitt Lymphoma 14Anemia, Refractory, with Excess of Blasts 14Lymphoma, B-Cell, Marginal Zone 13Leukemia, Myelomonocytic, Chronic 13Leukemia, Biphenotypic, Acute 13Graft vs Host Disease 13Hematologic Diseases 12Anemia, Aplastic 11Skin Neoplasms 10Ovarian Neoplasms 10

Interventions

Cisplatin 8Etoposide 6Paclitaxel 5Ifosfamide 4Sunitinib 3Oxaliplatin 3Cyclophosphamide 3Brentuximab Vedotin 3tremelimumab 2pembrolizumab 2etoposide phosphate 2durvalumab 2Sirolimus 2Gemcitabine 2Everolimus 2Epirubicin 2Dexamethasone 2Carboplatin 2Bleomycin 2Bevacizumab 2tozuleristide 1rolapitant 1ribociclib 1pegfilgrastim 1pazopanib 1olaparib 1fosaprepitant 1fludarabine phosphate 1fludarabine 1cabozantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Germ Cell and Embryonal × fludarabine × Clear all
NCT05634785 2026-01-09

CD30 CAR for CD30+ NSGCT

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
2 enrolled

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡